A number of things to consider:
- The Astra Zeneca deal with Accent Therapeutics was signed before the Cancer Cell paper with City of Hope findings was published
- Accent were formed with a focus on METTL3 (not FTO)
- The cancer cell paper buried the name of the drug used - labelling Bisantrene with a code name CS1. This had the effect that most of the news on the interwebs was referring to the compound as CS1 - not Bisantrene.
- I don't think Accent would make a song and dance about another research group identifying a competing drug just weeks after the deal with AstraZeneca was signed ( due to possible escape clauses for AstraZeneca in the early parts of the deal )
- Forums
- ASX - By Stock
- RAC media coverage
A number of things to consider: The Astra Zeneca deal with...
-
- There are more pages in this discussion • 2,097 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.82 |
Change
-0.005(0.27%) |
Mkt cap ! $309.9M |
Open | High | Low | Value | Volume |
$1.83 | $1.86 | $1.79 | $157.7K | 86.21K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5623 | $1.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.82 | 9999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2035 | 1.965 |
1 | 2000 | 1.850 |
1 | 111 | 1.820 |
1 | 5079 | 1.790 |
1 | 600 | 1.780 |
Price($) | Vol. | No. |
---|---|---|
1.810 | 400 | 1 |
1.820 | 9999 | 1 |
1.840 | 1500 | 1 |
1.860 | 2449 | 2 |
1.870 | 1200 | 1 |
Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online